Mixed treatment comparison of efficacy and tolerability of biologic agents in patients with rheumatoid arthritis
Marc C. Hochberg(University of Maryland, Baltimore), Tony Hebden(Bristol-Myers Squibb (Sweden)), Anagha Nadkarni(Bristol-Myers Squibb (Sweden)), Scott Berry(Queen's University), Lisa Rosenblatt(Bristol-Myers Squibb (Sweden)), Kristine Broglio(Berry & Associates (United States)), Digisha Trivedi(Bristol-Myers Squibb (Sweden))
Cited by 11
Related Papers
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
|Alzheimer s Research & Therapy|2021|818